A genetic variant c.553G &gt; T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug

Bogari, Neda M.; Aljohani, Ashwag; Amin, Amr; Al-Allaf, Faisal A.; Dannoun, Anas; Taher, Mohiuddin M.; Elsayed, Atalla; Rednah, Dareen Ibrahim; Elkhatee, Osama; Porqueddu, Massimo; Alamanni, Francesco; Khogeer, Soud; Fawzy, Ahmed

doi:10.1186/s12872-018-0965-3

Cited by 11 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…56 C>G was identified as a signal peptide functional mutant, which led to increased plasma TG and low HDL levels . Recently, a novel variant c.553 G>T (rs2075291) was also found to be relevant to TG levels in CAD patients who are on atorvastatin treatment …”

Section: Resultsmentioning

confidence: 99%

Pharmacogenetics of statins treatment: Efficacy and safety

Guan

et al. 2019

J Clin Pharm Ther

View full text Add to dashboard Cite

What is known and objective: Statins are widely used worldwide in the prevention and treatment of coronary atherosclerotic heart disease and ischaemic stroke.However, in clinical application, statins have shown great individual differences in terms of the efficacy and safety, some of which are related to genetic factors. The purpose of this article was to summarize the recent advances about the correlation between gene polymorphisms and the efficacy/safety of statins. Methods:We searched the databases including PharmGKB and PubMed (published before June 2019) using the keywords such as 'statin', 'gene polymorphism' and 'SNP' and obtained more than 100 articles. In this review, we described the clinical studies of genetic variants associated with both the efficacy and adverse reactions of statins.We also clarified the importance of taking pharmacogenetic variation into account to improve the clinical application of statins. Results and discussion:The available data were collected and analysed to present the polymorphisms of candidate genes encoding the most promising proteins including SLCO1B1 (encoding uptake transporters); ABCB1, ABCC2, ABCG2 (encoding effluent transporter); APOE, APOA5 (encoding apolipoprotein); genes encoding cytochrome P450 enzyme system; KIF6, HMGCR, LDLR, LPA, PCSK9, COQ2, CETP, etc These genes were proved to be related to the pharmacodynamics and pharmacokinetics of statins, thus affecting the efficacy and safety. What is new and conclusion:In this paper, the correlation between gene polymorphisms and the efficacy/safety of statins was summarized. The authors reached a consensus that the variants of the genes encoding uptake and effluent transporters have the most effect on the efficacy/safety of statins. It pointed out that it is desirable to do genetic testing of these transporter genes to reduce the incidence of myopathy or to achieve better outcomes before patients use statins, especially in the regions with high frequency of risk allele. K E Y W O R D S cytochrome P450, gene polymorphism, pharmacogenetics, statins, transporter | 859 GUAN et Al.

show abstract

Section: Resultsmentioning

confidence: 99%

Pharmacogenetics of statins treatment: Efficacy and safety

Guan

et al. 2019

J Clin Pharm Ther

View full text Add to dashboard Cite

show abstract

“…Continuous communications indicated new factors that influence interaction between inflammation and diabetes: the understanding the relations on nature and nurture [13], promoting health habits from children [14], the newest knowledge of the interaction between endothelial nitric oxide synthetase cholesteryl ester-transfer proteins and angiopoietin-like protein [15], gene expression in peripheral mononuclear cells [16], genetic variant and the altered triglycerides levels [17], and many others that opens new horizons in investigations.…”

Section: The Inflammatory Factormentioning

confidence: 99%

Cardiovascular events, diabetes and guidelines: the virtue of simplicity

Esper

Nordaby

2019

Cardiovasc Diabetol

View full text Add to dashboard Cite

Cardiovascular (CV) events or their minor syndromes, as various forms of ischemia, are medical emergencies that do not allow enough time for a guiding anamnesis or proper clinical examination, and lead to relying on Treatment Guidelines, but in many situations it is appropriate to deviate from them. Pathological studies have associated 75% of coronary artery events with atherosclerotic plaque rupture; it is now known that rupture alone is not enough for obstruction or occlusion of the vessel lumen. Concomitant conditions are required for the clinical manifestation of cardiovascular disease, including prothrombogenic and dysfunctional endothelium, less fibrinolytic capacity to protect it, increased platelet activation, increased adrenergic tone, microcirculation vasoconstriction, and other countless factors that contribute to thrombus formation, causing ischemia or infarction. But in most cases, repair of plaque rupture and re endothelization of the lesion are asymptomatic and silent. Atherosclerotic process is a chronic and progressive immune inflammation. Most of the therapeutic indications include statins, which cause side effects in 10% of patients, with a range varying between 7 and 21%, according to different authors. Many investigators have proved that statin use contribute to the genesis of diabetes, reports vary between 1 and 46%, where marked elevation of blood glucose fasting levels and glycosylated hemoglobin have been observed, be it by increased tissue resistance to insulin or by reduced β-cell insulin secretion. Physicians should base their indications on the recommendations provided by Guidelines, but they should not forget that every patient is different, and they should not get confused due to lack of time in an emergency nor be influenced by the latest publications or techniques until they have been properly tested.

show abstract

“…Numerous genes have been linked to TG metabolism, among which LPL, which encodes the lipoprotein lipase (LPL), has been shown to be play a major role (6,7). In addition to LPL, APOA5, encoding apolipoprotein A-V (apo A-V), is an important determinant of plasma TG levels (8)(9)(10). Apo A-V is mainly expressed in the liver and is present on and is exchanged between TRLs and high-density lipoprotein cholesterol (HDL-C) (11,12).…”

Section: Introductionmentioning

confidence: 99%